News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bio-Path Holdings, Inc. (BPTH) Reports Second Quarter 2014 Operational and Financial Results



8/18/2014 8:07:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., (NASDAQ:BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the second quarter ended June 30, 2014.

SECOND QUARTER 2014 OPERATIONAL AND FINANCIAL HIGHLIGHTS

Recent Operational Highlights

* The final patient of cohort six is currently being treated in the Phase I clinical trial evaluating Bio-Path’s lead product candidate, BP-100-1.01 (Liposomal Grb-2) in blood cancers. Assuming this patient successfully completes the treatment cycle, we anticipate concluding the sixth cohort of the study by the end of the third quarter.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES